Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol, Lieping Chen
Clinical Cancer Research (2013) Vol. 19, Iss. 5, pp. 1021-1034
Open Access | Times Cited: 466

Showing 1-25 of 466 citing articles:

Periodontitis: from microbial immune subversion to systemic inflammation
George Hajishengallis
Nature reviews. Immunology (2014) Vol. 15, Iss. 1, pp. 30-44
Open Access | Times Cited: 2348
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2040
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 1521
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane, Mohamed S. Abdel-Hakeem, E. John Wherry
Annual Review of Immunology (2019) Vol. 37, Iss. 1, pp. 457-495
Open Access | Times Cited: 1496
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W.L. Teng, Shin Foong Ngiow, Antoni Ribas, et al.
Cancer Research (2015) Vol. 75, Iss. 11, pp. 2139-2145
Open Access | Times Cited: 1310
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen, Xue Han
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3384-3391
Open Access | Times Cited: 1303
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla, et al.
Cancer Research (2014) Vol. 74, Iss. 19, pp. 5458-5468
Open Access | Times Cited: 1155
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia‐Wei Li, Seung-Oe Lim, Weiya Xia, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 895
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth, Shin Foong Ngiow, Antoni Ribas, et al.
Nature Reviews Clinical Oncology (2015) Vol. 13, Iss. 3, pp. 143-158
Closed Access | Times Cited: 845
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti, Kurt A. Schalper, Daniel Carvajal, et al.
Laboratory Investigation (2013) Vol. 94, Iss. 1, pp. 107-116
Open Access | Times Cited: 736
PD-L1 expression in human cancers and its association with clinical outcomes
Jinming Yu, Xin Wang, Feifei Teng, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 5023-5039
Open Access | Times Cited: 691
De-novo and acquired resistance to immune checkpoint targeting
Nicholas Syn, Michele W.L. Teng, Tony Mok, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 12, pp. e731-e741
Closed Access | Times Cited: 662
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim, Chia‐Wei Li, Weiya Xia, et al.
Cancer Cell (2016) Vol. 30, Iss. 6, pp. 925-939
Open Access | Times Cited: 652
Monoclonal Antibodies in Cancer Therapy
David J. Zahavi, Louis M. Weiner
Antibodies (2020) Vol. 9, Iss. 3, pp. 34-34
Open Access | Times Cited: 613
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero, David M. Berman, M. Ángela Aznar, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 8, pp. 457-472
Closed Access | Times Cited: 600
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Linh T. Nguyen, Pamela S. Ohashi
Nature reviews. Immunology (2014) Vol. 15, Iss. 1, pp. 45-56
Closed Access | Times Cited: 586
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Deborah Blythe Doroshow, Miguel F. Sanmamed, Katherine Hastings, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 15, pp. 4592-4602
Open Access | Times Cited: 558
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O’Donnell, Georgina V. Long, Richard A. Scolyer, et al.
Cancer Treatment Reviews (2016) Vol. 52, pp. 71-81
Closed Access | Times Cited: 505
Regulatory circuits of T cell function in cancer
Daniel E. Speiser, Ping‐Chih Ho, Grégory Verdeil
Nature reviews. Immunology (2016) Vol. 16, Iss. 10, pp. 599-611
Closed Access | Times Cited: 499
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica, Carrie Snyder, Todd Maney, et al.
Cancer Epidemiology Biomarkers & Prevention (2014) Vol. 23, Iss. 12, pp. 2965-2970
Closed Access | Times Cited: 482
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia‐Wei Li, Seung-Oe Lim, Ezra M. Chung, et al.
Cancer Cell (2018) Vol. 33, Iss. 2, pp. 187-201.e10
Open Access | Times Cited: 471
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Haidong Tang, Yong Liang, Robert A. Anders, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 2, pp. 580-588
Open Access | Times Cited: 466
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd, Katelyn T. Byrne, Rebecca A. Evans, et al.
Cancer Immunology Research (2015) Vol. 3, Iss. 4, pp. 399-411
Open Access | Times Cited: 429
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang, Yang Wang, Lukasz K. Chlewicki, et al.
Cancer Cell (2016) Vol. 29, Iss. 3, pp. 285-296
Open Access | Times Cited: 421
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das, Rakesh Verma, Mario Sznol, et al.
The Journal of Immunology (2014) Vol. 194, Iss. 3, pp. 950-959
Open Access | Times Cited: 413
Page 1 - Next Page

Scroll to top